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Abstract
Background: Germline mutations in the BRCA2 gene have been suggested to account for about
5% of familial prostate cancer; mutations have been reported in 2% of early onset (i.e.,  55 years)
prostate cancer cases and a segregating founder mutation has been identified in Iceland (999del5).
However, the role of BRCA2 in high risk prostate cancer pedigrees remains unclear.
Findings: We examined the potential involvement of BRCA2 in a set offive high-risk prostate
cancer pedigrees in which all prostate cases were no more distantly related than two meioses from
another case, and the resulting cluster contained at least four prostate cancer cases. We selected
these five pedigrees from a larger dataset of 59 high-risk prostate cancer pedigrees analyzed in a
genome-wide linkage screen. Selected pedigrees showed at least nominal linkage evidence to the
BRCA2 region on chromosome 13q. We mutation screened all coding regions and intron/exon
boundaries of the BRCA2 gene in the youngest prostate cancer case who carried the linked 13q
segregating haplotype, as well as in a distantly related haplotype carrier to confirm any segregation.
We observed no known protein truncating BRCA2 deleterious mutations. We identified one non-
segregating  BRCA2  variant of uncertain significance, one non-segregating intronic variant not
previously reported, and a number of polymorphisms.
Conclusion:  In this set of high-risk prostate cancer pedigrees with at least nominal linkage
evidence to BRCA2, we saw no evidence for segregating BRCA2 protein truncating mutations in
heritable prostate cancer.
Findings
Prostate cancer is the most frequently diagnosed cancer,
excluding basal and squamous cell skin cancers, and the
second leading cause of cancer death in men in the United
States. Significant familial clustering of prostate cancer
cases has been observed [1,2] suggesting that highly pen-
etrant prostate cancer predisposition genes exist.
Although a number of genes have been implicated in
prostate cancer (see Review articles [2-4]), most require
validation and functional studies to determine their pre-
cise role in the etiology of prostate cancer.
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One gene that has consistently been associated with pros-
tate cancer is BRCA2 (see Review article[5]). Early studies
in Iceland identified a BRCA2 founder mutation, 999del5,
that segregates with prostate cancer particularly in cases
diagnosed  65 years. [6,7] The Breast Cancer Linkage
Consortium has reported an increased risk of prostate
cancer in families with any known deleterious BRCA2
mutation[8] First-degree male relatives of women with
breast and/or ovarian cancer and a known BRCA2 muta-
tion were found to have an increased risk of prostate can-
cer (RR = 4.65), and rates were found to be even higher in
male relatives less than 65 years of age (RR = 7.33)[8]
However, a subsequent study of 22 families with a mini-
mum of three men affected with prostate cancer that also
included at least two cases of breast and/or ovarian cancer
observed no BRCA2  truncating mutations[9] Another
common BRCA2 founder mutation, 6174delT, has been
found to increase prostate cancer risk in some individuals
with Ashkenazi Jewish ancestry,[10] but these results have
not been confirmed in other studies [11-14]
It has been estimated that germline mutations in BRCA2
account for about 5% of prostate cancer in familial clus-
ters[15,16] However, other than the founder mutation in
Iceland and possibly another mutation in those with
Ashkenazi Jewish ancestry, the role of segregating BRCA2
mutations in familial prostate cancer remains unclear. To
further assess involvement of BRCA2 in familial prostate
cancer, we screened for BRCA2 variants in high-risk pros-
tate cancer pedigrees that showed at least nominal linkage
to the BRCA2 region on chromosome 13q.
Utah Prostate Cancer Resource
The vast majority of studied Utah high-risk prostate cancer
families have been identified using the Utah Population
Database (UPDB)[17] The UPDB is a computerized data-
base that links cancer information from the Utah Cancer
Registry (UCR) to genealogy information for almost four
million individuals who are, for the most part, descend-
ants of the nineteenth century pioneers to Utah. The UCR
began collecting statewide cancer records in 1966, and in
1973 the UCR became part of the National Cancer Insti-
tute's Surveillance, Epidemiology, and End Results (SEER)
Program. As a SEER site, all cancers in the state of Utah,
except basal and squamous cell skin cancers, are required
by law to be reported. Approximately 60% of cancer
records in the UCR link to a UPDB genealogy record. The
Utah population represented in the UPDB have been
shown to be similar to other Caucasian populations of
Northern and Western European descent [18] with nor-
mal levels of inbreeding[19] On rare occasions, families
with an excess of prostate cancer who reside outside of
Utah are contributed to the Utah Prostate Cancer High-
Risk Pedigree Resource by collaborators.
From the Utah High-Risk Prostate Cancer Pedigree
Resource of over 300 sampled pedigrees, we selected a
subset of the most informative prostate cancer pedigrees
for a genome-wide linkage search. [20] These pedigrees
satisfied the following two criteria: all cases were no more
distantly related than two meioses from another case and
the resulting cluster contained at least four cases. There
were no other exclusion criteria for the linkage analysis
including age at diagnosis, or other cancers or disease
states (e.g., breast cancer) within the family. We did not
remove any prostate cancer pedigrees from our High-Risk
Prostate Cancer Resource because of prior knowledge of a
BRCA2 mutation. We note that our high-risk prostate can-
cer pedigree definition is more strict than the usual defini-
tion of a high-risk prostate cancer pedigree[5] We
identified 59 pedigrees, from 3 to 6 generations in size,
containing 464 cases and an additional 1,261 unaffected
relatives. We genotyped 246 of the 464 cases, as well as
640 of the 1,261 unaffected relatives to infer genotypes of
deceased relatives or phase for genotyped cases. All
enrolled subjects gave informed consent, and this study
was approved by the University of Utah Institutional
Review Board.
Linkage analysis
Genotyping was performed by the Center for Inherited
Disease Research (CIDR) using a panel of 404 fluorescent
microsatellite (STR) markers spaced ~10 cM apart across
the genome. The laboratory methods used by CIDR are
described in detail at http://www.cidr.jhmi.edu. Mende-
lian inheritance was verified for all markers, and samples
with an inheritance incompatibility were set to missing.
Linkage analysis was performed using MCLINK, [21] a
Markov chain Monte-Carlo method that allows for fully
informative multilocus linkage analysis on large extended
pedigrees, using the Smith et al. prostate cancer inherit-
ance model. [22] MCLINK computes the robust
multipoint linkage statistic proposed by Göring and Ter-
williger, [23] referred to as theta LOD or TLOD[24] The
results of this genome-wide linkage scan are reported else-
where. [20]
We identified 5 pedigrees with at least nominally signifi-
cant linkage evidence (TLOD score  0.588) within
approximately 10 cM of the BRCA2 gene on chromosome
13q12.3 at 24.4–24.6 cM, using the Marshfield map. A
TLOD score of 0.588 corresponds to a p-value of 0.05, not
accounting for multiple testing. Table 1 provides details of
the linkage evidence for each pedigree. For two of the five
pedigrees (9445402 and 9990205), the highest genome-
wide TLOD score was at the chromosome 13q12 region.
For the remaining three pedigrees, the chromosome
13q12 peak was the second (9775803), third (9434307)
and fourth (9435901) highest of all peaks. For kindredBMC Research Notes 2009, 2:94 http://www.biomedcentral.com/1756-0500/2/94
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9775803, the 13q12 peak was preceded by a peak at 2q36-
q37. For kindred 9434307, the 13q12 peak was preceded
by peaks at 12q24 and 2p25-p24. Finally, for kindred
9435901, the 13q12 peak was preceded by peaks at
18p11-q22, 19q13, and 1p35-p34.
In each linked pedigree, we selected the youngest prostate
cancer case that carried a segregating haplotype of interest
as well as the most distantly related individual in the ped-
igree who also carried the same segregating haplotype for
BRCA2 mutation screening. One pedigree had two 13q
segregating haplotypes; both were screened for mutations.
Hence, twelve individuals were selected for BRCA2 muta-
tion screening. Ten of the subjects for mutation screening
were prostate cancer cases and two of the subjects were
unaffected relatives (1 male and 1 female) who carried the
13q segregating haplotype.
BRCA2 mutation screening
All coding regions and intron/exon boundaries of the
BRCA2 gene were screened for mutations using 47 primer
pairs that have been described previously. [25] Shorter
exons were amplified in a single fragment and longer
exons were amplified as sub fragments. There were five
fragments for exon 10, 16 fragments for exon 11, and two
fragments for each of the following exons: 14, 18, and 27.
PCR reactions were performed in a reaction volume of 10
l containing 5 ng of genomic DNA, 1 mM dNTPs, 1.5
mM or 2.5 mM MgCl2, 1 M of both the forward and
reverse primer, and 0.25 U Amplitaq DNA polymerase
(Applied Biosystems, Foster City CA).
PCR products were cleaned using the ExoSAP-IT method
(USB Corporation, Cleveland, OH). DNA sequencing
reactions were conducted using BigDye® Terminator v3.1
Cycle Sequencing Kits (Applied Biosystems, Foster City
CA) and sequence data were obtained on both forward
and reverse PCR primers on ABI 3730xl Genetic Analyzer
(Applied Biosystems, Foster City CA). Contigs were
assembled using PhredPhrap/Consed[26] Polymor-
phisms were detected using Polyphred [27] and Mutation-
Surveyor [28] by two independent researchers. All variants
were unanimously confirmed.
Summary characteristics of the five screened pedigrees are
shown in Table 1. In four of the five pedigrees, the linked
13q segregating haplotype was carried by the majority of
prostate cancer cases. The age at diagnosis varied from
what would be considered an early-onset case (i.e.,  55
years – two prostate cancer cases), to cases with a diagno-
sis over the age of 80 years (six cases).
Next, for each pedigree we identified the common ances-
tor hypothesized to carry the 13q segregating haplotype.
For all of the descendants of this ancestor, we identified
all individuals with diagnosis of a known BRCA2-associ-
ated cancer (breast cancer, prostate cancer, ovarian cancer,
pancreatic cancer, and melanoma) using linked UCR data.
These results are shown in Table 2. In each pedigree, the
number of prostate cancer cases among descendants of
this most distant ancestor significantly exceeded that
expected in a population matched by birth year (within
five years), sex, and place of birth (Utah versus outside of
Utah): p-value range: 0.007–0.000006. For pedigree
9445402, the number of melanoma cases also exceeded
the matched population rate (p-value: 0.031). Although
four of the five families had at least one known breast can-
cer case, there were no pedigrees with a significant excess
of breast cancer cases. Furthermore, we observed no male
breast cancer cases in any pedigree. The Utah Prostate
High-Risk Cancer Resource is continually updated from
the UPDB with new descendant information and newly
diagnosed prostate cancer cases. Differences in the
number of prostate cancer cases exist between Tables 1
and 2. Table 1 contains information on the pedigree struc-
ture and sampling design used in the original linkage
Table 1: Characteristics of five high-risk prostate cancer pedigrees showing linkage evidence to chromosome 13q, BRCA2 region1
Pedigree Identifier2 Max TLOD score on 
chr 13q
Location of max 
TLOD on chr 13
# prostate cancer cases 
in pedigree (genotyped)
# prostate cancer cases 
carrying segregating 13q 
haplotype3
Age at prostate cancer 
diagnosis (yrs)
9775803 1.423 23.0 cM 9(6) 7 57, 59, 61, 61, 64, 73, 
74, 84, 87
9445402 1.191 23.0 cM 5(3) 5 60, 60, 78, 79, 82
9990205 1.050 36.0 cM 10(5) 3 59, 61, 62, 65, 66, 66, 
70, 73, 77, 78
9434307 0.976 29.0 cM 12(6) 6, 74 52, 59, 59, 63, 63, 69, 
72, 74, 75, 76, 80, 85
9435901 0.953 23.0 cM 6(1) 4 54, 57, 62, 64, 67, 82
1Pedigrees defined in Table 1 are based on the pedigree structure used for the linkage analysis.
2Pedigree identifier modified to protect confidentiality of pedigree members.
3Haplotype carrier status may be inferred based on descendant information rather than directly genotyped.
4Two distinct 13q haplotypes segregated within the pedigree.BMC Research Notes 2009, 2:94 http://www.biomedcentral.com/1756-0500/2/94
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analysis. Table 2 reflects current cancer information for
each pedigree.
No known deleterious mutations in BRCA2 were observed
among the 12 carriers of the chromosome 13q haplo-
types. We observed one BRCA2 variant of unknown signif-
icance as defined by the Breast Cancer Information Core
(BIC) [29] database and one variant not listed in the BIC
database (see Table 3). The variant of unknown signifi-
cance (5972CT) was detected in an unaffected male 1st
cousin (last known age to be cancer free: 72 years) but was
not carried by the sampled prostate cancer case in the ped-
igree (diagnosis age: 54 years). The intronic variant not
previously reported in the BIC database (IVS14 -62AG)
was observed in a single prostate cancer case, but it was
not detected in the other haplotype carrier tested in the
pedigree.
We also observed a number of BRCA2 polymorphisms
that are likely of no biological consequence (see Table 4).
Many of these polymorphisms have been reported in
other individuals with prostate cancer, and the majority
segregated within pedigrees.
Our results are consistent with a growing pool of evidence
that BRCA2 plays at most a minor role in causing prostate
cancer in high-risk prostate cancer families. As with our
results, Sinclair et al. [9] using high-risk prostate cancer
pedigrees found no BRCA2  truncating mutations, but
found one previously reported missense mutation and
two previously unreported intronic polymorphisms.
Gayther et al. [16] found two germ-line BRCA2 truncating
mutations in 38 high-risk, familial prostate cancer pedi-
gree in two individuals diagnosed  56 years, neither of
which was found to segregate. A recent study by Agalliu et
al. using 266 subjects in high-risk prostate cancer families
also reported no disease-associated protein truncating
BRCA2  mutations[30] Our study is unique in that we
focused on pedigrees with strong linkage evidence near
Table 2: Risk of BRCA2 associated cancers in descendants of most distant ancestor carrying the 13q haplotype1
Pedigree Identifier # descendants Cancer type # of observed cancers # of expected cancers p-value
9775803 380 Breast 1 1.41 0.755
Prostate 9 2.15 0.0004
9445402 206 Breast 2 0.79 0.188
Melanoma 2 0.27 0.031
Prostate 6 0.70 0.00009
99902052 NA NA NA NA NA
9434307 1,863 Breast 5 5.36 0.621
Melanoma 4 2.25 0.190
Prostate 22 7.13 0.000006
Ovary 1 0.88 0.585
9435901 204 Breast 1 0.73 0.516
Melanoma 1 0.30 0.261
Prostate 5 1.17 0.007
1 The following cancers were considered to be BRCA2 associated cancers: breast, prostate, ovarian, pancreatic, and melanoma.
2Pedigree 9990205 was contributed from a collaborator outside of Utah, and does not link to the UPDB. The number of cancers in descendants 
from this pedigree cannot be determined.
Table 3: BRCA2 variants of unknown significance observed in Utah high-risk prostate cancer pedigrees
Exon/Intron Nucleotide change Amino Acid change Desc. On BIC1 No. found in prostate cases
/total found
/no. with valid results2
Pedigree segregation
11 5972C>T M1915T UV(7) 0/1/12 --3
I14 IVS14-62A>G Intronic NA 1/1/12 --
1UV = unclassified variant. Value in parentheses represents the number of times there is an entry for the given mutation in the BIC database.
2Valid result requires that the sequencing reaction is of sufficient quality as to detect the polymorphism.
3This variant was previously reported to be present in prostate cancer cases by others.21BMC Research Notes 2009, 2:94 http://www.biomedcentral.com/1756-0500/2/94
Page 5 of 6
(page number not for citation purposes)
the BRCA2 gene region on chromosome 13q, and that all
pedigrees met a very strict definition of high-risk.
While the five linked pedigrees studied here appear to
have minimal involvement of the most likely candidate
gene in the region (i.e., BRCA2), there is still unexplained
linkage evidence on chromosome 13q that cannot be
attributable to BRCA2 coding mutations. There may be yet
unidentified regulatory BRCA2 mutations, deletions, and/
or rearrangements that were not screened as part of this
study. Alternatively, the nominal linkage evidence in
these prostate cancer pedigrees may represent other pros-
tate cancer predisposition genes located near BRCA2
including  HMG1,  LGR8,  CCNA1,  TRPC4, and FOXO1.
Finally, the results may be spurious as only a limited
number of pedigrees (i.e., five of the original 59 pedi-
grees) were studied, and segregation analysis with chro-
mosome 13q may not be the most reliable way of
identifying BRCA2 mutation families.
Conclusion
This study adds further evidence that BRCA2 has a limited
role in heritable prostate cancer. We observed no evidence
for BRCA2 coding mutations segregating within our Utah
high-risk prostate cancer pedigrees with prior linkage evi-
dence to chromosome 13q.
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